Tyrosine kinase inhibitors (nibs) and monoclonal antibodies (mabs) are all the rage over the past decade – and they are revolutionising areas of medicine we’ve had no effective treatment for. Myelofibrosis is the latest to be reviewed, with a JAK 1 and 2 inhibitor that’s brand new.
Looking at spleen size, the authors considered a reduction more than 35% as significant – no one in the standard therapy group achieved this, where as over a quarter in the ruxolitinib group did.
The future of myelofibrosis? Pretty likely. Check it out here, in the latest NEJM.
source | NEJM
image | hic et nunc